



NEWS FROM SHARSHERET

BREAST CANCER AWARENESS MONTH UPDATE

OCTOBER 2026



At just 30 years old and with two young children, Aliza Bochner never expected to find a breast cancer diagnosis after a routine self-check.

Today, Aliza is a triple negative breast cancer survivor, mother, and advocate who has turned her experience into a source of hope and support for others. After recently welcoming a new baby through a surrogate, she is embracing this new chapter with her growing family.

Hear Aliza share her story, the role Sharsheret has played throughout her journey, and why she is passionate about being there for others facing cancer.

A Mother's Strength: Aliza's Triple Negative Breast Cancer Story

News & Notes

Know the Signs, Symptoms, and Your Risk of Breast Cancer

1 in 40 people of Ashkenazi Jewish descent and 1 in 140 people of Sephardi Jewish descent carry a BRCA gene mutation, making Jewish families 10 times more susceptible to



hereditary breast, male breast, ovarian, prostate, melanoma, and pancreatic cancer than the general population. It is important to know the signs and symptoms and your family history of breast cancer and other cancers. Have questions about your risk? Contact Sharsheret's genetic counselors.

Sharsheret's Genetics for Life program is sponsored by [AstraZeneca](#) and [Basser Center for BRCA](#).

[Contact a Genetic Counselor](#)



Order a Free Breast Cancer Survivorship Kit

If you haven't received yours yet, order a Sharsheret Survivorship Kit designed for breast cancer survivors. Each free kit includes exercise bands to help you kickstart a workout routine and a healthy living cookbook filled with simple, nourishing recipes to support your wellness journey.

The Thriving Again Breast Cancer Survivorship program is made possible with generous support from [Exact Sciences](#), [Lilly](#), [Merck](#), and The Heimann, Polis and Sacks Families in loving memory of Nicole Sacks.

[Order Your Kit](#)



The Official 2027 National Mah Jongg League Card Pre-Sale is LIVE!

Order your card and enjoy your favorite game while supporting Sharsheret. Sharsheret receives \$7 from the NMJL for every card purchased, helping support women, men, and families facing cancer. Cards will be mailed directly from the NMJL in April 2027.

Order deadline is Monday, January 25, 2027.

[Order Your Cards](#)



Upcoming Webinar: The AI Revolution in Cancer Screening

Join us on October 8 for a cutting-edge look at how Artificial Intelligence is shaping breast cancer detection and prevention. Learn about the latest research, including the PRISM study, advances in risk assessment, and emerging developments in

ovarian cancer screening. Leave with actionable strategies to advocate for the most up-to-date, tech-forward care.

Don't miss other Summit webinars on topics including [healthy cooking](#), [menopause and cancer](#), and [GLP-1s and cancer](#).

The Sharsheret Summit is sponsored by Cooperative Agreement 24-0061 of the Centers for Disease Control and Prevention, [AstraZeneca](#), [GSK](#), [Pfizer](#), [Lilly](#), [Eisai](#), [Weill Cornell Medicine Genetics and Personalized Cancer Prevention Program](#), and [Smart State](#).

[Register for Summit Webinars](#)

THE **EARLY** ACT

Legislative Update

The bipartisan EARLY Act (Breast Cancer Education and Awareness Requires Learning Young Act) Reauthorization just cleared an important hurdle in Congress! The EARLY Act specifically prioritizes Ashkenazi Jewish populations due to their significantly elevated genetic risks. To learn more about supporting this bill and other important legislation focused on breast cancer, [visit the website](#) of Sharsheret partner Hadassah.

[Learn More](#)



Make a Difference This Thanksgiving, One Pie at a Time!

Place a dessert order today and help raise vital funds for women and families facing ovarian cancer.

Every pie is accompanied by life-saving cancer educational resources. As you gather with loved ones this Thanksgiving, take the opportunity to have meaningful conversations about health, early detection, and genetic awareness. For more information, please contact Maya Tochner at mtochner@sharsheret.org.

About Pies for Prevention:

Launched in 2008 by sisters Adeena Sussman and Sharon Wieder in memory of their mother and grandmother, both lost to ovarian cancer, Pies for Prevention raises funds and awareness in the days leading up to Thanksgiving. Proceeds support the Stephanie Sussman and Ann Nadrich Memorial Jewel and Sharsheret's Ovarian Cancer Program.

Pies for Prevention is sponsored by [Merck](#).

[Find a Local Sale](#)



Introducing the Mammo-Grant: Screen, Then Pay It Forward

This Breast Cancer Awareness Month, Sharsheret is introducing the Mammo-Grant, a new way to turn one important act of self-care into support for others.

Get a mammogram, then give a Mammo-Grant donation to Sharsheret to help provide support, education, counseling, and financial assistance to people facing or at increased risk for breast cancer.

[Learn More](#)

Upcoming Annual Events



JOIN US FOR A
DAY OF STRENGTH

OCTOBER 9TH

RA'ANANA CITY TENNIS CENTER

[CLICK HERE TO REGISTER](#)

OR VISIT SHARSHERET.ORG/ISRAEL-TENNIS

**JOIN
TEAM
SHARSHERET**

**ACS MAKING STRIDES AGAINST
BREAST CANCER WALK**

**Sunday, October 18
Central Park**

[Click Here to Register](#)

**TEAM
SHARSHERET**

SPONSORED BY
Bernstein
Liebhard



SHARSHERET

West Coast Dash

5K | 10K | Family Fun Race (1K)

Playa del Rey, CA

See you at the beach!

[CLICK HERE TO REGISTER](#)

Visit sharsheret.org/westcoast for more information.

**SUNDAY
10.25.2026**



SHARSHERET

NEW YORK CITY BENEFIT

TUESDAY, NOVEMBER 17, 2026 | 6:00 PM

[REGISTER NOW](#)

FOR MEN AND WOMEN

MAIMONIDES AWARD



DR. ELISA PORT
CHIEF OF BREAST SURGERY,
MOUNT SINAI HEALTH SYSTEM

WOMAN OF VALOR



LANI KOLLANDER
SHARSHERET AMBASSADOR

GUEST SPEAKER



LEANDRA MEDINE
COHEN
WRITER AND STYLIST

HOSTED BY



KIM KUSHNER
BEST-SELLING KOSHER,
COOKBOOK AUTHOR,
SHARSHERET BOARD OF DIRECTORS

25 YEARS

Latest Podcast



From "Second-in-Command" to Nonprofit CEO

In a new episode of *The Nonprofit CEO Spark*, Sharsheret CEO Elana Silber sits down with host Marcia Beckner to discuss succeeding founder Rochelle Shoretz A"H, honoring her legacy, and continuing to grow Sharsheret while staying true to its mission. Tune in to hear Elana share insights on Sharsheret's evolution, leadership transitions, and building a strong organizational culture.

[Listen Here](#)

Recent Blogs



From Fear to Freedom: My BRCA2 Experience

In recognition of Previvor Day on September 30, Joanna shares her story of learning she carried a BRCA2 mutation and facing difficult decisions about her health and future. Read her story of turning fear into control and finding freedom through knowledge.

[Read Joanna's Story](#)

Sponsored Content



ALISCA®-Breast1: A Phase 2 Study of Alisertib, an Investigational Drug, in Combination with Endocrine Therapy, in Patients with HR+, HER2-Negative Recurrent or Metastatic Breast Cancer



Alisertib is an investigational drug and it has not been approved by any health authority. Safety and efficacy of alisertib have not been established.

Puma Biotechnology understands the importance of making clinical trial information clearer and more accessible for people with metastatic breast cancer. Clinical trials can sometimes feel overwhelming, which is why Puma has created straightforward, easy-to-read resources about the ALISCA®-Breast1 clinical trial, currently open for enrollment:

- Clinical Trial Information Sheet
- Questions to Ask Your Oncologist

Find them here: <https://bit.ly/ALISCA-Breast1>

Having information can help you feel more prepared and support more informed conversations with your healthcare team.

Interested in learning about new treatments?

After your advanced breast cancer progresses on hormone therapy and a CDK4/6 inhibitor, it may feel like your options are limited. **Now, there's more to explore.**

**A new breast cancer treatment
has been FDA approved!**

[Learn more](#)

celcuity

© 2026 Celcuity Inc. All rights reserved. US-61B-26-0233 08/26

PYNNACLE BY 220C

The pivotal PYNNACLE Phase 2 clinical trial (NCT04585750) is enrolling patients with locally advanced or metastatic ovarian and endometrial cancer with a *TP53* Y220C mutation.

Click for more information and to find a PYNNACLE clinical trial site near you:

[PYNACLEStudy.com](https://pynnaclestudy.com)

You can also visit: clinicaltrials.gov/study/NCT04585750

To contact the PMV Pharmaceuticals Clinical Study Information Center, please use:
clinicaltrials@pmvpharma.com

MA-585-0167 April 2026



Looking for support?

Call 866.474.2774 or email info@sharsheret.org.



©2026 Sharsheret, a 501(c)3 charitable organization. Sharsheret is a national not-for-profit cancer support, education, and financial assistance organization and does not provide any medical advice or perform any medical procedures. Sharsheret does not endorse or promote any specific medication, treatment, product or service, and makes no guarantees regarding the effectiveness of any product discussed herein. Any information provided herein is not a substitute for professional medical

advice or treatment. You should always seek the advice of your physician or other qualified health provider.

[Privacy Policy](#) | [Terms of Use](#)



Sharsheret | 10 East 40th Street 28th Floor | New York, NY 10016 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)